265 filings
Page 2 of 14
SC 13G/A
1jjs829wxz21eb
9 Feb 24
Eton Pharmaceuticals / Opaleye Management ownership change
4:05pm
8-K
bap1pwmg mt
2 Feb 24
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
6:55am
8-K
5f7zsrahdjh3vy2n lgr
9 Nov 23
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
12:00am
8-K
gt78svc0ifmvj3iox
4 Oct 23
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
6:55am
8-K
cfl3ib77
10 Aug 23
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
4:15pm
8-K
f5ew299 cmky
5 Jul 23
Termination of a Material Definitive Agreement
4:15pm
8-K
fw6k6idm4ubm7l5n
28 Jun 23
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
6:55am
8-K
pfnr8oc3na7i g87f0d
15 Jun 23
Entry into a Material Definitive Agreement
4:18pm
8-K
i5m2 3g78
13 Jun 23
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
smjpw71kr6a ok34w
11 May 23
Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
4:15pm
8-K
i3xh8bl
10 May 23
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution
6:50am
EFFECT
3tyyilc27 op
3 May 23
Notice of effectiveness
12:15am
CORRESP
nn8z4sthzthct1sd5q3x
1 May 23
Correspondence with SEC
12:00am
UPLOAD
0mu9 6jd07qr0xrm
12 Apr 23
Letter from SEC
12:00am
S-8
gx1a6gz lk
20 Mar 23
Registration of securities for employees
8:20pm